Tech Center 1600 • Art Units: 1634 1646 1674
This examiner grants 59% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18363859 | NANOPORE BIOSENSORS FOR DETECTION OF PROTEINS AND NUCLEIC ACIDS | Non-Final OA | Katholieke Universiteit Leuven |
| 18359483 | PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18333172 | COMPOSITIONS AND METHODS FOR TARGETED CYTOKINE DELIVERY | Non-Final OA | Washington University |
| 19055378 | METHODS OF ENHANCING EFFICACY OF IMMUNOCONJUGATES USING PAIRED HUMAN ANTIBODIES TARGETED AT NON-OVERLAPPING B-CELL EPITOPES ON THE SAME ANTIGEN | Final Rejection | Medicovestor, Inc. |
| 17486394 | COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES | Final Rejection | The Trustees of Columbia University in the City of New York |
| 18028498 | ZIP12 ANTIBODY | Non-Final OA | IP2IPO INNOVATIONS LIMITED |
| 17905453 | USE OF ANTI-FAM19A1 ANTAGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | Non-Final OA | NEURACLE SCIENCE CO., LTD. |
| 18325283 | BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF | Non-Final OA | Universiteit Gent |
| 17716467 | ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18052476 | SERINE PROTEASE MOLECULES AND THERAPIES | Final Rejection | Research Development Foundation |
| 18470875 | ANTI-CD25 ANTIBODY AGENTS | Non-Final OA | Cancer Research Technology Limited |
| 17487164 | NANOPORES WITH INTERNAL PROTEIN ADAPTORS | Final Rejection | Rijksuniversiteit Groningen |
| 17288524 | T-Cell Receptors and Uses Thereof | Non-Final OA | The Council of the Queensland Institute of Medical Research |
| 18492958 | LINKER PEPTIDE FOR CONSTRUCTING FUSION PROTEIN | Non-Final OA | AMPSOURCE BIOPHARMA SHANGHAI INC. |
| 18304801 | MUTANT G-PROTEIN COUPLED RECEPTORS AND METHODS FOR SELECTING THEM | Final Rejection | NXERA PHARMA UK LIMITED |
| 17915567 | RNA COMPOSITIONS TARGETING CLAUDIN-18.2 | Non-Final OA | BioNTech SE |
| 18193979 | TGFbeta1-BINDING IMMUNOGLOBULINS AND USE THEREOF | Final Rejection | SCHOLAR ROCK, INC. |
| 18000010 | METHODS AND COMPOSITIONS FOR TREATING, PREVENTING THE ONSET AND/OR SLOWING PROGRESSION OF OSTEOARTHRITIS | Non-Final OA | New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special |
| 18253756 | ANTI-GALECTIN-9 ANTIBODIES AND THERAPEUTIC USES THEREOF | Non-Final OA | PureTech LYT, Inc. |
| 18145588 | ANTIBODIES RECOGNIZING SORTILIN | Final Rejection | Prothena Biosciences Limited |
| 17441849 | PHOTOACTIVE ANTIBODIES | Non-Final OA | UEA ENTERPRISES LIMITED |
| 17514898 | NEUROPILIN ANTIBODY NASAL SPRAY TO REDUCE COVID-19 TRANSMISSION | Final Rejection | MARV ENTERPRISES LLC |
| 17438303 | MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS | Non-Final OA | Surrozen Operating Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy